Kirti Sharma: Immune Thrombocytopenia Market Set for Strong Growth Through 2036

Kirti Sharma, Market Research Analyst at DelveInsight Business Research LLP, shared a post on LinkedIn:

“Immune Thrombocytopenia (ITP) Market Set for Strong Growth Through 2036

The Immune Thrombocytopenia market is experiencing notable transformation with the rise of targeted biologics and immunotherapies. While current treatments primarily focus on symptom management and maintaining platelet counts, newer therapies are designed to target the underlying immune pathways.

With a robust pipeline, growing awareness, and ongoing innovation, the ITP market is positioned for significant growth through 2036.

Immune Thrombocytopenia (ITP) Market Set for Strong Growth Through 2036, Driven by Targeted Therapies and Biologics | DelveInsight

Immune Thrombocytopenia (ITP) is defined as a decrease in platelet count due to immune processes, leading to an increased risk of bleeding. Primary ITP, with no underlying condition, accounts for nearly 80% of cases, while secondary ITP is associated with conditions such as systemic lupus erythematosus, infections, and certain drugs.

ITP is a heterogeneous autoimmune disorder that can present with symptoms ranging from petechiae, purpura, and bruising to severe bleeding events such as gastrointestinal hemorrhage or intracranial bleeding.

The disease may follow a chronic course in adults, requiring long-term management and significantly impacting patient quality of life.

Key Immune Thrombocytopenia (ITP) Companies in the Market Landscape

The key Immune Thrombocytopenia companies in the market include:

• Novartis
• Takeda
• Pfizer
• Genosco/Oscotec
• UCB Biopharma, and others

Immune Thrombocytopenia (ITP) Market Insights and Epidemiology

Epidemiological data highlight the growing burden of ITP across the seven major markets (7MM).

In 2025, the total prevalent cases of ITP in the 7MM were approximately 187,800 cases, which are expected to increase during the forecast period.

The United States accounted for the highest number of cases, with around 67,500 diagnosed prevalent cases in 2025, and is expected to grow further by 2036.

Additionally, nearly 30,000 new cases of ITP are diagnosed annually in the US, indicating a significant disease burden.

The Immune Thrombocytopenia market size in the 7MM was valued at approximately USD 4,000 million in 2025, and is expected to grow steadily through 2036.

Trending keywords shaping the market include thrombocytopenia, autoimmune platelet destruction, TPO receptor agonists, FcRn inhibitors, and biologic therapies.

Immune Thrombocytopenia (ITP) Treatment Analysis

For many years, immune-modulating therapies such as corticosteroids, intravenous immunoglobulins (IVIG), splenectomy, and rituximab have been the cornerstone of ITP treatment.

Current treatment options include:

• Thrombopoietin receptor agonists (PROMACTA, NPLATE, DOPTELET)
• Anti-CD20 antibodies (RITUXAN)
• SYK inhibitors (TAVALISSE)
• FcRn inhibitors (VYVGART)
• Immunomodulatory agents and splenectomy

Despite these options, many patients relapse or become refractory to first-line treatments, necessitating second-line therapies.

Thrombopoietin receptor agonists play a crucial role by enhancing platelet production and have significantly transformed the treatment landscape.

Recent Developments in the Immune Thrombocytopenia (ITP) Market

Recent advancements highlight strong innovation in ITP treatment:

• In February 2026, Sanofi announced a new clinical study evaluating the impact of early multi-immune modulation with rilzabrutinib in adult patients with Immune Thrombocytopenia (ITP) who failed first-line treatment. The study includes a screening period of up to 8 weeks, a primary analysis period of up to 28 weeks, a long-term extension period for selected participants of 28 weeks, and a 24-week follow-up period for eligible patients.
• In January 2026, Ouro Medicines received U.S. FDA Fast Track Designation for gamgertamig for the treatment of Immune Thrombocytopenia (ITP). The designation is intended to accelerate development and regulatory review, highlighting the therapy’s potential to address unmet needs in patients with autoimmune blood disorders.

These developments reflect a shift toward targeted and mechanism-driven therapies.

Immune Thrombocytopenia (ITP) Emerging Therapies

Key emerging therapies in the ITP pipeline include:

• Ianalumab (Novartis) – BAFF-R inhibitor with dual mechanism of action
• Mezagitamab (Takeda) – anti-CD38 monoclonal antibody
• PF-06835375 (Pfizer) – CXCR5 antagonist
• Cevidoplenib (Genosco/Oscotec) – SYK inhibitor

Ianalumab is currently in Phase III development and expected to be submitted for regulatory review around 2027.

Mezagitamab is also in Phase III trials and anticipated for regulatory filing between 2027 and 2029.

These therapies aim to provide targeted immunomodulation and improved long-term outcomes.

Immune Thrombocytopenia (ITP) Market Drivers and Barriers

Immune Thrombocytopenia Market Drivers:

• Increasing prevalence and diagnosis rates
• Growing adoption of second- and third-line therapies
• Advancements in targeted biologics and immunotherapies
• Strong pipeline with innovative mechanisms of action

Immune Thrombocytopenia Market Barriers:

• High relapse rates and treatment resistance
• Long-term dependency on therapies
• High cost of biologics and advanced treatments
• Limited efficacy in refractory patient populations

Immune Thrombocytopenia (ITP) Report Highlights:

• The ITP market is expected to grow significantly during the forecast period (2026–2036).
• Increasing disease burden and improved diagnosis will drive market expansion.
• Current therapies remain effective but require long-term management.
• Emerging therapies with novel mechanisms are expected to reshape the treatment landscape.
• The report provides comprehensive insights into epidemiology, market size, and pipeline developments.

Conclusion

The Immune Thrombocytopenia market is undergoing a significant transformation with the emergence of targeted biologics and immunotherapies.

While existing treatments focus on symptom control and platelet count management, newer therapies aim to address underlying immune mechanisms.

With a strong pipeline, increasing awareness, and continuous innovation, the ITP market is poised for substantial growth through 2036.”

Stay updated with Hemostasis Today.